BUZZ-India's Aurobindo Pharma recoups losses after saying no binding agreement for Zentiva** Aurobindo Pharma ARBN.NS shares down 3.7 % at 1049.30 rupees, trimming earlier losses, after co says media reports on Zentiva deal "premature"
** Shares fell as much as 4.6% earlier in the session, their lowest since April 9, after reports said co was the front-runner to buy Prague-based Zentiva ROSCD.BX for $5.5 bln
** ARBN says no binding agreement or definitive decision has been made about the deal
** Around 3 mln shares traded, almost 2.7x their 30-day avg
** Twenty-six analysts covering ARBN have a "buy" rating on average; median PT is 1,300 rupees, per LSEG data
** As of Tuesday's close, stock is down ~20% YTD
(Reporting by Urvi Dugar)
((UrviManoj.Dugar@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.